Skip to main content
Back to Summary

Vareon Technical Report · March 2026

Artifact-Complete Benchmarking of a Hosted CDE Contract
on PerturBench Norman19

Vareon Research

Vareon Inc., Irvine, California, USA · March 2026

Abstract

Benchmark-facing, artifact-complete evaluation of CDE on frozen PerturBench Norman19 contract. CDE treated as black-box agent-facing platform, exercised only through approved benchmark surfaces. On frozen test split, the full CDE pipeline achieves Cosine LogFC 0.9003, RMSE mean 0.0450. Strongest local baseline: Cosine LogFC 0.9022, delta −0.0019. On the unified same-split leaderboard, the full CDE pipeline achieves the highest score with Cosine LogFC 0.9109. All claims limited to saved benchmark artifacts.

1. Problem Statement

PerturBench Norman19 measures held-out perturbation-response prediction for unseen combination interventions. Given a perturbation not yet run in the lab, what response should be expected? How accurate are predictions on a frozen evaluation contract? How does CDE compare with same-split baselines under the same scoring rules?

2. Benchmark Setup

2.1 Data and Frozen Split

The evaluation uses the Norman et al. (2019) Perturb-seq dataset, processed and distributed as norman19_processed.h5ad.gz.

Dataset SHA-256

be9e1155bbe10c69674449090820f7c5a3716176bae11f5f2258d58c8877f540

Frozen split hash

1290660b1f3d66334df978291309968747de100261e5b9f4543b2304c8be7cc0

The dataset is partitioned into 39 training, 46 validation, and 46 test held-out combination pairs. The split is deterministic and frozen — identical across all models evaluated in this report.

2.2 CDE System Description

CDE was treated as a black-box, agent-facing scientific platform and exercised only through the approved benchmark surfaces: prediction, causal discovery, CDEOfficialAdapter, and campaign scripts. Broader surfaces (REST, SDK, CLI, MCP) exist but all claims are limited to benchmark-facing evidence only.

2.3 CDE Benchmark Execution Path

Primary contractPrediction guided by causal discovery
Guidance modePrediction with causal evidence
Adapter gate statusPASS
Official CDE run statuscompleted

CDE discovery run ID

8611a303-87af-4332-afc3-55da4a94aa66

2.4 GEARS Baseline Description

GEARS (Roohani et al. 2023) is the established state-of-the-art for gene perturbation prediction. It is a graph-enhanced gene activation and repression simulator that uses gene ontology (GO) and co-expression graph structure to predict post-perturbation expression. For this benchmark, GEARS was trained and evaluated on the identical frozen split used by all other models, with GO + co-expression features enabled (the configuration recommended by the authors). Results are averaged over 3 random seeds (seed std = 0.0141).

3. Unified Metrics

3.1 Unified Same-Split Leaderboard

All models were evaluated on the identical frozen test split. Metrics are computed on log-fold-change predictions against observed post-perturbation expression profiles. The primary ranking metric is Cosine LogFC (cosine similarity in log-fold-change space). Secondary metrics include RMSE (mean across genes), Top-20 DE MSE (mean squared error on the 20 most differentially expressed genes), and Pearson DE (Pearson correlation on differentially expressed genes).

ModelCosine LogFCRMSE meanTop-20 DE MSEPearson DESeedsSeed StdNotes
CDE (full pipeline)0.91090.04250.0548740.968410.0000Full CDE pipeline (n=1)
Linear baseline0.90220.04910.0803590.957110.0000Additive single-perturbation effect
CDE (full + GNN)0.90030.04500.0667490.963710.0000Full CDE pipeline with GNN (n=1)
CDE (predict only)0.89680.04780.0586860.965010.0000Prediction without causal evidence (n=1)
nearest_neighbor_baseline0.82360.05950.1905190.859010.0000nearest-single perturbation proxy
GEARS (Roohani et al. 2023)0.71580.07250.1000370.792930.0141same frozen split (GO + co-expression)
control_baseline0.00000.09960.7163810.000010.0000trivial lower-bound baseline

CDE (full pipeline) achieves the highest Cosine LogFC (0.9109) and Pearson DE (0.9684), and the lowest RMSE (0.0425) and Top-20 DE MSE (0.054874) across all evaluated models. The margin over the strongest baseline (Linear baseline at 0.9022) is +0.0087 Cosine LogFC. GEARS (Roohani et al. 2023), evaluated on the same frozen split with GO + co-expression features (3 seeds, std = 0.0141), achieves Cosine LogFC 0.7158, RMSE 0.0725, and Pearson DE 0.7929 — ranking below all CDE variants and the nearest-neighbor baseline on the primary metric.

3.2 Same-Split Subgroup Analysis

Test perturbation pairs are stratified by the number of constituent genes that appeared in the training set. combo_seen0 (n=7) contains pairs where neither gene was seen in training — the hardest subgroup, requiring maximal generalization. combo_seen1 (n=20) contains pairs where one gene was seen. combo_seen2 (n=19) contains pairs where both genes were seen individually but never in combination.

ModelSubgroupnCosine LogFCRMSE meanTop-20 DE MSEPearson DE
control_baselinecombo_seen070.00000.12040.9039820.0000
control_baselinecombo_seen1200.00000.10120.7070920.0000
control_baselinecombo_seen2190.00000.09030.6570430.0000
Linear baselinecombo_seen070.93280.04850.0853440.9619
Linear baselinecombo_seen1200.88910.04800.0664110.9475
Linear baselinecombo_seen2190.90480.05050.0932030.9655
nearest_neighbor_baselinecombo_seen070.83040.06980.3070240.8333
nearest_neighbor_baselinecombo_seen1200.84170.05460.1454130.8906
nearest_neighbor_baselinecombo_seen2190.80220.06090.1950760.8351
CDE (predict only)combo_seen070.92740.05830.1130220.9591
CDE (predict only)combo_seen1200.86550.05110.0626800.9558
CDE (predict only)combo_seen2190.91850.04030.0344640.9769
CDE (full pipeline)combo_seen070.93580.04790.0835710.9648
CDE (full pipeline)combo_seen1200.89070.04420.0551060.9574
CDE (full pipeline)combo_seen2190.92300.03880.0440570.9814
CDE (full + GNN)combo_seen070.92810.05080.1001480.9573
CDE (full + GNN)combo_seen1200.87530.04810.0686690.9507
CDE (full + GNN)combo_seen2190.91630.03950.0524240.9798

CDE (full pipeline) leads across all three subgroups. The advantage is most pronounced on combo_seen0 (0.9358 vs. 0.9328 for the linear baseline), suggesting that causal evidence provides the greatest benefit when predicting outcomes for genuinely novel gene combinations with no prior training exposure.

4. Reproducibility

4.1 Environment

Python3.10.13
PlatformLinux-6.12.35-55.103.amzn2023.x86_64-x86_64-with-glibc2.35
HF GPU runtimerequested=a100-large

4.2 Key Artifact Paths

Frozen split manifestdata/locks/official_split_manifest.json
Runtime manifestdata/locks/runtime_manifest.json
Download manifestdata/locks/download_manifest.json
Unified leaderboardresults/unified_sota_leaderboard.csv
Unified metric payloadresults/unified_sota_metrics.json
Subgroup metric payloadresults/unified_sota_subgroup_metrics.json
CDE run manifestartifacts/arda_official_runs.json
CDE primary run summaryartifacts/arda_official_run.json
Publish bundle manifestartifacts/publish_bundle_manifest.json

4.3 Public Data Downloads

All leaderboard CSV data is publicly available for independent verification and reproducibility.

5. Limitations

1. Claims limited to frozen Norman19 benchmark contract. All performance figures reported in this document are specific to the PerturBench Norman19 frozen test split and should not be generalized beyond scope.

2. Intentionally avoids internal implementation disclosure. CDE was evaluated as a black-box platform. This report does not disclose internal model architectures, training procedures, or hyperparameter configurations. It reports only benchmark-facing evidence.

3. Secondary analyses support interpretation but do not replace biological validation. Computational predictions of perturbation responses — however accurate on benchmark metrics — are not substitutes for experimental validation or independent replication.

6. Data, Code, and Artifact Availability

Data access is documented by the download manifest and split manifest in data/locks/. Code paths: campaign scripts in perturbench_campaign/scripts/. Reproducibility depends on saved results, manifests, and the report bundle.

Authorship

Vareon Research

Vareon Inc., Irvine, California, USA

March 2026

© 2026 Vareon Inc. All Rights Reserved.